Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID19 therapy

Wong, Henry Sung-Ching; Guo, Chin-Lin; Lin, Gan-Hong; Lee, Kang-Yun; Okada, Yukinori; Chang, Wei-Chiao

The recent outbreak of coronavirus disease 2019 (COVID-19) by SARS-CoV-2 has led to uptodate 24.3 M cases and 0.8 M deaths. It is thus in urgent need to rationalize potential therapeutic targets against the progression of diseases. An effective, feasible way is to use the pre-existing ΔORF6 mutant of SARS-CoV as a surrogate for SARS-CoV-2, since both lack the moiety responsible for interferon antagonistic effects. By analyzing temporal profiles of upregulated genes in ΔORF6-infected Calu-3 cells, we prioritized 55 genes and 238 ligands to reposition currently available medications for COVID-19 therapy. Eight of them are already in clinical trials. Of particular importance is the emergence of immune checkpoint inhibitors targeting PD-L1 that have not been used in COVID-19 treatment. We also pinpointed 16 drug groups from the Anatomical Therapeutic Chemical classification system, with the potential to mitigate symptoms of SARS-CoV-2 infection and thus to be repositioned for COVID-19 therapy.